153 related articles for article (PubMed ID: 11222361)
1. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma.
Niitsu N; Okabe-Kado J; Okamoto M; Takagi T; Yoshida T; Aoki S; Hirano M; Honma Y
Blood; 2001 Mar; 97(5):1202-10. PubMed ID: 11222361
[TBL] [Abstract][Full Text] [Related]
2. Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma.
Niitsu N; Okamoto M; Okabe-Kado J; Takagi T; Yoshida T; Aoki S; Honma Y; Hirano M
Leukemia; 2001 May; 15(5):832-9. PubMed ID: 11368446
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
4. Serum nm23-H1 protein as a prognostic factor in hematological malignancies.
Okabe-Kado J
Leuk Lymphoma; 2002 Apr; 43(4):859-67. PubMed ID: 12153176
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic relation of nm23-H1/NDPK-A with leukemia and lymphoma].
Li HY; Liu JS; Wang YF
Sheng Li Ke Xue Jin Zhan; 2003 Jan; 34(1):74-7. PubMed ID: 12778818
[No Abstract] [Full Text] [Related]
6. Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma.
Niitsu N; Honma Y; Iijima K; Takagi T; Higashihara M; Sawada U; Okabe-Kado J
Leukemia; 2003 Jan; 17(1):196-202. PubMed ID: 12529678
[TBL] [Abstract][Full Text] [Related]
7. [Serum levels of mm23-H1 protein and their clinical implications in malignant lymphoma].
Niitsu N
Rinsho Ketsueki; 2001 Dec; 42(12):1155-61. PubMed ID: 11828717
[No Abstract] [Full Text] [Related]
8. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma.
Niitsu N; Nakamine H; Okamoto M; Akamatsu H; Honma Y; Higashihara M; Okabe-Kado J; Hirano M;
Br J Haematol; 2003 Nov; 123(4):621-30. PubMed ID: 14616965
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia.
Niitsu N; Okabe-Kado J; Nakayama M; Wakimoto N; Sakashita A; Maseki N; Motoyoshi K; Umeda M; Honma Y
Blood; 2000 Aug; 96(3):1080-6. PubMed ID: 10910925
[TBL] [Abstract][Full Text] [Related]
10. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness.
Aryee DN; Simonitsch I; Mosberger I; Kos K; Mann G; Schlögl E; Pötschger U; Gadner H; Radaszkiewicz T; Kovar H
Br J Cancer; 1996 Dec; 74(11):1693-8. PubMed ID: 8956779
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma.
Niitsu N; Nakamine H; Okamoto M; Akamatsu H; Higashihara M; Honma Y; Okabe-Kado J; Hirano M
Clin Cancer Res; 2004 Apr; 10(7):2482-90. PubMed ID: 15073128
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome.
Ito Y; Okabe-Kado J; Honma Y; Iwase O; Shimamoto T; Ohyashiki JH; Ohyashiki K
Leukemia; 2002 Feb; 16(2):165-9. PubMed ID: 11840281
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the nm23-H1 protein and their clinical implication in extranodal NK/T-cell lymphoma.
Niitsu N; Okamoto M; Honma Y; Nakamine H; Tamaru JI; Nakamura S; Yoshino T; Higashihara M; Hirano M; Okabe-Kado J;
Leukemia; 2003 May; 17(5):987-90. PubMed ID: 12750720
[No Abstract] [Full Text] [Related]
14. [Clinical significance of biological prognostic factors in non-Hodgkin lymphoma: analysis of serum and cell surface nm 23-H1 protein].
Niitsu N
Rinsho Ketsueki; 2003 Apr; 44(4):211-8. PubMed ID: 12784653
[No Abstract] [Full Text] [Related]
15. Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia.
Wakimoto N; Yokoyama A; Okabe-Kado J; Nagata N; Motoyoshi K; Honma Y
Br J Cancer; 1998 Jun; 77(12):2298-303. PubMed ID: 9649149
[TBL] [Abstract][Full Text] [Related]
16. nm23-H1 expression in non-Hodgkin and Hodgkin lymphomas.
Bircan S; Inamdar KV; Rassidakis GZ; Medeiros LJ
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):207-14. PubMed ID: 18301251
[TBL] [Abstract][Full Text] [Related]
17. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
Yokoyama A; Okabe-Kado J; Wakimoto N; Kobayashi H; Sakashita A; Maseki N; Nakamaki T; Hino Ki; Tomoyasu S; Tsuruoka N; Motoyoshi K; Nagata N; Honma Y
Blood; 1998 Mar; 91(6):1845-51. PubMed ID: 9490665
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of nm23 protein expression in renal cell carcinomas.
Nakagawa Y; Tsumatani K; Kurumatani N; Cho M; Kitahori Y; Konishi N; Ozono S; Okajima E; Hirao Y; Hiasa Y
Oncology; 1998; 55(4):370-6. PubMed ID: 9663430
[TBL] [Abstract][Full Text] [Related]
19. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
20. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
